


OIPE



RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/068,905

DATE: 04/11/2002 TIME: 12:58:06

Input Set : A:\78490-7 Seq 04-02-02 v1.txt
Output Set: N:\CRF3\04112002\J068905.raw

```
3 <110> APPLICANT: Lemaire, Simon
              Bernatchez-Lemaire, Irma
              Le, Hoang-Thanh
      7 <120> TITLE OF INVENTION: Histogranin-like Peptides and Non-peptides, Processes
              for Their Preparation and Uses Thereof
     10 <130> FILE REFERENCE: 78490-7
C--> 12 <140 > CURRENT APPLICATION NUMBER: US/10/068,905
C--> 12 <141> CURRENT FILING DATE: 2002-02-07
     12 <160> NUMBER OF SEQ ID NOS: 9
     14 <170> SOFTWARE: PatentIn version 3.0
     16 <210> SEQ ID NO: 1
     17 <211> LENGTH: 15
     18 <122> TYPE: PRT
C--> 19 <213> ORGANISM: Artificial
     21 <220> FEATURE:
     22 <223> OTHER INFORMATION: Prior art peptide synthesized by solid-phase
     23
              procedure
     25 <400> SEQUENCE: 1
     27 Met Asn Tyr Ala Leu Lys Gly Gln Gly Arg Thr Leu Tyr Gly Phe
     30 <210> SEQ ID NO: 2
     31 <211> LENGTH: 15
     32 <212> TYPE: PRT
C--> 33 <213> ORGANISM: Artificial
     35 <220> FEATURE:
     36 <223> OTHER INFORMATION: Prior art peptide synthesized by solid-phase
     37
              procedure
     39 <400> SEQUENCE: 2
     41 Val Val Tyr Ala Leu Lys Arg Gln Gly Arg Thr Leu Tyr Gly Phe
     42: 1
     44 <210> SEQ ID NO: 3
     45 <211> LENGTH: 14
     46 <212> TYPE: PRT
C--> 47 <213> ORGANISM: Artificial
     49 <220> FEATURE:
     50 <223> OTHER INFORMATION: Prior art peptide synthesized by solid-phase
              procedure
     53 <400> SEQUENCE: 3
     55 Ala Leu Lys Arg Gln Gly Arg Thr Leu Tyr Gly Phe Gly Gly
     56 1
     58 <210> SEQ ID NO: 4
     59 <211> LENGTH: 9
```

60 <212> TYPE: PRT

DATE: 04/11/2002

TIME: 12:58:06

Input Set : A:\78490-7 Seq 04-02-02 v1.txt Output Set: N:\CRF3\04112002\J068905.raw C--> 61 <213> ORGANISM: Artificial 63 -: 220> FEATURE: 64 <223> OTHER INFORMATION: Prior art peptide synthesized by solid-phase procedure 67 -(400> SEQUENCE: 4 69 Gly Gln Gly Arg Thr Leu Tyr Gly Phe 70) 1 72 <210> SEQ ID NO: 5 73 -2115 LENGTH: 4 74 <2125 TYPE: PRT C--> 75 <213> ORGANISM: Artificial 77 -(220> FEATURE: 78 <223> OTHER INFORMATION: Cyclic tetrapeptide synthesized by solid-phase procedure 81 +220> FEATURE: W--> 82 <221> NAME/KEY: Xaa 83 -1222> LOCATION: (2)..(2) 84 <223> OTHER INFORMATION: Xaa is p-Cl-Phe 87 -: 220: FEATURE: W--> 88 <221> NAME/KEY: Xaa 89 +2225 LOCATION: (4)..(4) 90 -223> OTHER INFORMATION: Xaa is (D)-Arg 93 <400> SEQUENCE: 5 W--> 95 Gly Xaa Tyr Xaa 96 1 98 <210> SEQ ID NO: 6 99 <211> LENGTH: 4 100 <212> TYPE: PRT C--> 101 <213> ORGANISM: Artificial 103 <220> FEATURE: 104 -: 223 > OTHER INFORMATION: Cyclic tetrapeptide synthesized by solid-phase 105 procedure 107 <220> FEATURE: W--> 108 <221> NAME/KEY: Xaa 109 < 222 > LOCATION: (2)...(2)110 - 223> OTHER INFORMATION: Xaa is p-Cl-Phe 113 <220> FEATURE: W--> 114 <221> NAME/KEY: Xaa 115 < 222 > LOCATION: (4)..(4)116 <223> OTHER INFORMATION: Xaa is p-amino-Phe 119 -: 400> SEQUENCE: 6 W--> 121 Gly Xaa Tyr Xaa 122 - 1124 <210> SEQ ID NO: 7 125 <211> LENGTH: 4 126 <212> TYPE: PRT C--> 127 <213> ORGANISM: Artificial

130 <223> OTHER INFORMATION: Cyclic tetrapeptide synthesized by solid-phase

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/068,905

129 <220> FEATURE:

## RAW SEQUENCE LISTING

DATE: 04/11/2002 TIME: 12:58:06

PATENT APPLICATION: US/10/068,905

Input Set : A:\78490-7 Seq 04-02-02 v1.txt
Output Set: N:\CRF3\04112002\J068905.raw

procedure 133 <220> FEATURE: W--> 134 <221> NAME/KEY: Xaa 135 <222> LOCATION: (2)..(2) 136 <223> OTHER INFORMATION: Xaa is p-Cl-Phe 139 <220> FEATURE: W--> 140 <221> NAME/KEY: Xaa 141 <222> LOCATION: (4)..(4) 142 <223> OTHER INFORMATION: Xaa is p-guanidino-Phe 145 <400> SEQUENCE: 7 W--> 147 Gly Xaa Tyr Xaa 148 1 150 <210> SEQ ID NO: 8 151 <211> LENGTH: 4 152 <212> TYPE: PRT C--> 153 <213> ORGANISM: Artificial 155 <220> FEATURE: 156 <223> OTHER INFORMATION: Cyclic tetrapeptide synthesized by solid-phase procedure 159 <220> FEATURE: W--> 160 <221> NAME/KEY: Xaa 161 <222> LOCATION: (2)..(2) 162 < 223 > OTHER INFORMATION: Xaa is p-amino-Phe 165 <220> FEATURE: W--> 166 <221> NAME/KEY: Xaa 167 <222> LOCATION: (4)..(4) 168 <223> OTHER INFORMATION: Xaa is (D)-Arg 171 <400> SEQUENCE: 8 W--> 173 Gly Xaa Tyr Xaa 174 1 176 <210> SEQ ID NO: 9 177 <211> LENGTH: 4 178 <212> TYPE: PRT C--> 179 <213> ORGANISM: Artificial 181 <220> FEATURE: 182 <223> OTHER INFORMATION: Cyclic tetrapeptide synthesized by solid-phase 183 procedure 185 <220> FEATURE: W--> 186 <221> NAME/KEY: Xaa 187 <222> LOCATION: (2)..(2) 188 <223> OTHER INFORMATION: Xaa is p-Cl-Phe 191 <220> FEATURE: W--> 192 <221> NAME/KEY: Xaa 193 <222> LOCATION: (4)..(4) 194 <223> OTHER INFORMATION: Xaa is (D)-Arg 197 <400> SEQUENCE: 9 W--> 199 Thr Xaa Tyr Xaa

200 1

## VERIFICATION SUMMARY

DATE: 04/11/2002 TIME: 12:58:07

PATENT APPLICATION: US/10/068,905

Input Set : A:\78490-7 Seq 04-02-02 v1.txt
Output Set: N:\CRF3\04112002\J068905.raw

L:12 M·270 C: Current Application Number differs, Replaced Current Application No L:12 M:271 C: Current Filing Date differs, Replaced Current Filing Date L:19 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:1 L:33 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:2 L:47 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:3 L:61 M·220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:4 L:75 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:5 L:82 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5 L:88 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5 L:95 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 L:101 M:220 C: Keyword misspelled or invalid format,  $\pm 213 > 0 RGANISM$  for SEQ ID#:6 L:108 M:257 W: Feature value mis-spelled or invalid, -221> Name/Key for SEQ ID#:6 L:114 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:6 L:121 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 L:127 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:7 L:134 M:257 W: Feature value mis-spelled or invalid, +221> Name/Key for SEQ ID#:7 L:140~M:257~W: Feature value mis-spelled or invalid,  $\cdot:221>$  Name/Key for SEQ ID#:7 L:147 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 L:153 M:220 C: Keyword misspelled or invalid format, +213> 0RGANISM for SEQ ID#:8 L:160 M:257 W: Feature value mis-spelled or invalid,  $\cdot ...221>$  Name/Key for SEQ ID#:8 L:166 M:257 W: Feature value mis-spelled or invalid,  $\cdot:221>$  Name/Key for SEQ ID#:8 L:173 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 L:179 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:9 L:186 M:257 W: Feature value mis-spelled or invalid, -221> Name/Key for SEQ ID#:9 L:192 M:257 W: Feature value mis-spelled or invalid,  $<\!221\!>$  Name/Key for SEQ ID#:9 L:199 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9